Article Text

PDF

Future use of the Glasgow alcoholic hepatitis score
  1. I N Guha,
  2. W M Rosenberg
  1. University of Southampton, Liver Unit, Southampton, UK
  1. Correspondence to:
    Dr I N Guha
    Mail point 811, Level D, Southampton General Hospital, Trenoma Rd, Southampton S016 6YD, UK; guhaneil{at}hotmail.com

Statistics from Altmetric.com

We read with interest the findings of Forrest and colleagues (Gut 2005;54:1174–9) regarding their prognostic algorithm for alcoholic hepatitis, the Glasgow alcoholic hepatitis score (GAHS). The study uses robust clinical end points to develop an algorithm that has diagnostic advantages over the modified discriminant function score (DFS). We would like to discuss some of the future implications of this important study.

The overall death rate in the study was 23% at 28 days and the death rate of patients with a DFS >32 was 29% at 28 days in the derivation population. The latter figure is lower than the placebo arms of many of the randomised controlled trials of alcoholic hepatitis that range between 35% and 50%.1–3 This difference compared with the published literature may be attributable to case definition. It is possible that there were a fewer number of patients in the derivation cohort for GAHS with true alcoholic hepatitis. Some of the previous studies of alcoholic hepatitis have required liver biopsy evidence of alcoholic hepatitis as part of the case definition. This was not the case for entry into the derivation cohort for the GAHS study and the case definition was based solely on clinical and biochemical evidence of liver dysfunction in patients with heavy alcohol consumption. In the validation population there was biopsy evidence of alcoholic hepatitis in only 33%.

While this may invalidate the GAHS as a means of identifying cases of alcoholic hepatitis, it does not invalidate its use in identifying patients at risk of death when admitted to hospital with liver dysfunction on a background of heavy alcohol use. This makes it far more pragmatic than tests based on biopsies as many hospitals do not have access to specialised services to perform transjugular liver biopsies in the acute setting. Furthermore, there are published randomised controlled trials which have not required histological evidence of alcoholic hepatitis before allocating treatment.1,4 The corollary to this is that although alcoholic hepatitis often presents with clinical features of fever, leucocytosis, and hyperbilirubinaemia, there remains a differential diagnosis which may require a biopsy to resolve.5

It is important to differentiate between true alcoholic hepatitis and severe liver dysfunction in patients with heavy alcohol consumption because it will influence the choice of intervention. Randomised controlled trials that use GAHS to identify patients with alcoholic hepatitis might be greatly underpowered if the therapy (for example, steroids) is effective in alcoholic hepatitis but ineffective or harmful in other clinical conditions where abnormal clinical parameters might be associated with heavy alcohol consumption. Selection of risk stratification models should be determined by the severity of the adverse effects of the therapy under trial. Those with more severe adverse effects will warrant models with high specificity whereas drugs with minimal side effects will benefit from a model with a high sensitivity. Compared with the DFS, the GAHS has an increased specificity, decreased sensitivity, and improved accuracy, making it suited to the selection of subjects in studies using more toxic therapies.

The utility of the GAHS will depend on the effect of its use in the care of patients. We suggest that the next step in the evaluation of GAHS should be a clinical trial to see if patients randomised to risk stratification with GAHS followed by appropriate interventions have a better outcome than those managed conventionally.

We believe this is an excellent study using robust clinical end points. It is a practical model which can be used easily at the bedside to give valuable prognostic information. Success of future therapeutic trials in alcoholic hepatitis will not only depend on the efficacy of the drug but also the appropriate selection of patients by models and their respective cut off points.

References

View Abstract

Footnotes

  • IN Guha received grant support from Pfizer.

  • W M Rosenberg is a consultant for Schering-Plough, Roche, Gilead, Bayer, and Pfizer. He is the Chief Scientific Officer for HepCGen.

  • Conflict of interest: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.